Efficacy of first- or second-line latanoprost on intraocular pressure and ocular symptoms in patients with open-angle glaucoma or ocular hypertension;Efficacité du latanoprost, donné en première ou deuxième intention, sur la pression intra-oculaire et la symptomatologie oculaire chez des patients présentant un glaucome à angle ouvert ou une hypertension oculaire simple

Journal Francais d'Ophtalmologie

Volumn 29, Issue 6, 2006, Pages 615-624

  Baudouin, C ^a   Rouland, J F ^b   Nordmann, J P ^a   Bron, A ^c   Pelen, F ^d  

^a CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c HÔPITAL DU BOCAGE   (France)

^d PFIZER INC   (United States)

Author keywords

Latanoprost; Ocular hypertension; Open angle glaucoma; Prostaglandin

Indexed keywords

ANTIGLAUCOMA AGENT; EYE DROPS; LATANOPROST;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EYE IRRITATION; EYE PAIN; FEMALE; GLAUCOMA SYMPTOM SCALE; HUMAN; HYPEREMIA; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OPEN ANGLE GLAUCOMA; OPEN STUDY; PATIENT COMPLIANCE; PHASE 4 CLINICAL TRIAL; PROGNOSIS; RATING SCALE; SEX RATIO; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL SYSTEM;

EID: 33746855001     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0181-5512(06)73821-9     Document Type: Article

References (25)

1. Bechetoille A. Les glaucomes. Volumes 1 et 2. Japperenard : Angers ; 2001.
2. European Glaucoma Society. Guide pour les glaucomes. 2003.
3. Leonard R. Statistics on Vision impairment: A resource manual (5th edition). Gordon Research Institute: New-York, USA, 2002.
4. Bron A. Traitement des glaucomes. Rev Prat, 2001;51:2198-201.
5. Baudouin C, Bechetoille A, Bron A, et al. Intérêt de la mesure de la qualité de vie (QDV) et de l'observance thérapeutique chez les patients atteints de glaucome chronique à angle ouvert. J Fr Ophtalmol, 2000;23:1057-64.
6. Lee BL, Gutierrez P, Gordon M, et al. The Glaucoma Symptom Scale. A brief index of glaucoma-specific symptoms. Arch Ophthalmol, 1998;116:861-6.
7. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology, 1993;100:1297-304.
8. Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology, 1996;103:138-47.
9. Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology, 1995;102:1743-52.
10. Mishima HK, Masuda K, Kitazawa Y, et al. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study. Arch Ophthalmol, 1996;114:929-32.
11. Watson P, Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology, 1996;103:126-37.
12. O'Donoghue EP, for the UK and Ireland Latanoprost Study Group. A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: A 3-month, randomised study. Br J Ophthalmol, 2000;84:579-82.
13. Larsson LI, Mishima HK, Takamatsu M, et al. The effect of latanoprost on circadian intraocular pressure. Surv Ophthalmol, 2002;47 Suppl 1:S90-6.
14. Orzalesi N, Rossetti L, Invernizzi T, et al. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci, 2000;41:2566-73.
15. Alm A, Widengard I. Latanoprost: experience of 2-year treatment in Scandinavia. Acta Ophthalmol Scand, 2000;78:71-6.
16. Watson PG. Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group. Ophthalmology, 1998;105:82-7.
17. Susanna R, JR, Sheu WP. Comparison of latanoprost with fixed-combination dorzolamide and timolol in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label, parallel-group, multicenter study in Latin America. Clin Ther, 2004;26:755-68.
18. Fechtner RD, Airaksinen PJ, Getson AJ, et al. Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. Acta Ophthalmol Scand, 2004;82:42-8.
19. Hedman K, Larsson LI. The effect of latanoprost compared with timolol in African-American, Asian, Caucasian, and Mexican open-angle glaucoma or ocular hypertensive patients. Surv Ophthalmol, 2002;47 Suppl 1:S77-89.
20. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol, 2002;120:1268-79.
21. Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol, 2003;121:48-56.
22. Zimmerman TJ, Stewart WC. Intraocular pressure, safety, and quality of life in glaucoma patients switching to latanoprost from monotherapy treatments. J Ocul Pharmacol Ther, 2003;19:405-15.
23. Lee MD, Fechtner FR, Fiscella RG, et al. Emerging perspectives on glaucoma: highlights of a roundtable discussion. Am J Ophthalmol, 2000;130 (4 Suppl):S1-11.
24. Perry CM, McGavin JK, Culy CR, Ibbotson T. Latanoprost: an update of its use in glaucoma and ocular hypertension. Drugs Aging, 2003;20:597-630.
25. Schumer RA, Camras CB, Mandahl AK. Latanoprost and cystoid macular edema: is there a causal relation? Curr Opin Ophthalmol, 2000;11:94-100.